Sana Pharma News
Home
» Sana Pharma News
14
Nov
202211/14/2022
Sana Pharma participated in the Sixth International Conference of the Jordanian Psychiatric Association during 25-26 August 2022 at the LandMark hotel.
من مشاركة سنا لصناعة الادوية في المؤتمر...
14
Nov
202211/14/2022
Sana pharma participated in the First Levant Endocrinology and Diabetes congress. It was a wonderful and educational experience. It took place from November 2, 2022 to November 5th, 2022.
من مشاركة...
14
Nov
202211/14/2022
من مشاركة شركة سنا للصناعات الدوائية في "مؤتمر جمعية أطباء الصدرية الأردنية" الذي أقيم بتاريخ 17/6/2022-16 في قصر المؤتمرات في الهيلتون البحر الميت.
Sana Pharma participated in the "Updates in...
13
Nov
202211/13/2022
Sana Pharma proudly announces the release of a new medication in the Jordanian market.
Empaxa, Empagliflozin is an oral antidiabetic medication used for the treatment of type 2 diabetes patients....
12
Nov
202211/12/2022
Sana Pharma proudly announces the release of a new medication in the Jordanian market.
Clotexia, Apixaban, is an oral direct factor Xa inhibitor that inhibits both free and clot-bound factor Xa,...
11
Nov
202211/11/2022
Sana Pharma proudly announces the release of a new medication in the Jordanian market.
Oprexa, Olanzapine, is an oral atypical antipsychotic, that is used for the treatment of schizophrenia and of...
17
Sep
202209/17/2022
Sana Pharma proudly announces the release of two new medications in the Jordanian market. Vorasan, Vortioxetine, the first and only antidepressant that improves cognitive function associated with...
17
Sep
202209/17/2022
Sana Pharma registered a new anticoagulant medication, Clotexia, for the treatment and prevention of blood clots, and it will be available soon in the Jordanian market.
16
Jan
202201/16/2022
Sana Pharma is the first Jordanian pharmaceutical company to submit Molnupiravir registration file to Jordanian Food and Drug Administration (JFDA). Molnupiravir has recently been approved by the US...
09
Jan
202201/09/2022
Sana Pharma announces the registration of the first two biological products with the Jordanian Food and Drug Administration (JFDA):
Bevasan (Bevacizumab 100 mg and 400 mg)
Biosimilar to Avastin (...